Boehringer Ingelheim (Germany)

Ingelheim am Rhein (Germany de)
Pulmonary and Respiratory Medicine
Empagliflozin Nintedanib Type 2 Diabetes Clinical endpoint Tolerability Afatinib Linagliptin Treatment Idiopathic Pulmonary Fibrosis Insulin Therapy
Watch Introduction

Bibliometric indicators

Evolution over the last years of activity

Showing the period - Sept. 2024

13,388
Activity
3%

Total documents

2.37
Impact
3%

Normalized Impact

2,719
Excellence
3%

Highly Cited Papers (Top 10%)

69.5
Leadership
3%

Leadership (%)

45.7
Mobility & Collaboration
3%

International Collaboration (%)

411
Excellence
3%

Outstanding papers (Top 1%)

11.5
Leadership
3%

Women Leading (%)

5.8
Leadership
3%

Women Leading International (%)

33.9
Open Access
3%

Open Access (%)

Main Research Fields (top 9 by publications)

Indicators:

Net Change
3%

Net Change
3%

Net Change
3%

Net Change
3%

Net Change
3%

Net Change
3%

Net Change
3%

Net Change
3%

Net Change
3%

Human Resources

Historical perspective

From to Sept. 2024

Current resources

Quick filters

Career Stage
Occasional Junior Researcher Senior Leading
Performance
Standard Good Excellent Outstanding
Gender
Male Female
Reset
0

Personnel

0.0

Papers / Personnel

0

Leading women (%)

0
0

Gender (%)

0

Papers / Permanent researchers

0

Papers / Leading researchers

Career stage

Performance

Years of Activity

ONE Index (distribution)

ONE Index by Main Research Fields

ONE Index vs. Years of Activity

Main authors

ID Name Gender Discipline Career Stage ONE Index Years Activity NDocs RCI HCP Leader Collab.
1 Nordaby, Matias male Cardiology and Cardiovascular Medicine Researcher 895 9 50 5.32 13 0.0% 70.0%
2 Ettore D Capoluongo Economics and Econometrics Junior researcher 891 1 4 0.00 0 0.0% 100.0%
3 Broedl, Uli male Endocrinology, Diabetes and Metabolism Senior researcher 889 23 138 12.59 59 42.0% 63.0%
4 Woerle, Hans-Juergen male Endocrinology, Diabetes and Metabolism Senior researcher 874 25 181 7.47 79 38.1% 69.1%
5 Maximilian Von Eynatten Endocrinology, Diabetes and Metabolism Senior researcher 867 23 163 6.31 52 29.5% 65.0%
6 Viollet, Coralie female Molecular Biology Researcher 842 10 58 3.10 18 12.1% 56.9%
7 Rehbein, Steffen male Small Animals Leading researcher 834 32 159 1.34 22 69.2% 43.4%
8 George, Jyothis male Endocrinology, Diabetes and Metabolism Leading researcher 827 63 233 4.29 74 19.7% 53.2%
9 Koitka‐Weber, Audrey female Endocrinology, Diabetes and Metabolism Researcher 816 8 36 4.89 15 22.2% 77.8%
10 Stefan, Hantel Endocrinology, Diabetes and Metabolism Senior researcher 814 19 107 10.90 32 14.0% 66.4%
11 Okafo, George male Junior researcher 813 3 13 76.62 9 0.0% 92.3%
12 Jung, Marc male Junior researcher 813 3 13 76.62 9 0.0% 92.3%
13 David Michael Wyatt Political Science and International Relations Leading researcher 805 62 296 1.13 38 79.7% 9.1%
14 Stowasser, Susanne female Pulmonary and Respiratory Medicine Senior researcher 803 17 202 5.11 45 7.4% 93.1%
15 Degroote, Matthias male Artificial Intelligence Researcher 800 14 62 5.48 23 11.3% 41.9%
16 Mattheus, Michaela female Endocrinology, Diabetes and Metabolism Researcher 786 14 137 10.20 36 0.7% 68.6%
17 Hans Jurgen Woerle Endocrinology, Diabetes and Metabolism Senior researcher 784 23 121 7.41 19 31.4% 69.4%
18 Bluhmki, Erich male Epidemiology Leading researcher 783 33 112 15.14 47 25.9% 57.1%
19 Pekcec, Anton male Cellular and Molecular Neuroscience Senior researcher 778 19 69 1.87 16 46.4% 44.9%
20 Hengerer, Bastian male Cellular and Molecular Neuroscience, Molecular Biology Leading researcher 772 37 151 2.56 40 17.9% 49.0%
21 Garidel, Patrick male Molecular Biology Senior researcher 764 29 210 1.77 43 45.2% 22.9%
22 Quaresma, Manuel male Pulmonary and Respiratory Medicine Researcher 761 10 117 3.86 24 1.7% 92.3%
23 Zeller, Cordula male Endocrinology, Diabetes and Metabolism Researcher 761 12 47 29.83 26 2.1% 89.4%
24 Søren Søgaard Lund Endocrinology, Diabetes and Metabolism Senior researcher 755 24 85 1.85 19 43.5% 49.4%
25 Déruaz-Luyet, Anouk female Endocrinology, Diabetes and Metabolism Researcher 746 10 73 1.72 17 12.3% 50.7%
895
One Index
 Nordaby, Matias PhD   0000-0003-1760-1550 50 docs (2016 - 2024)  
Anticoagulant Therapy , Dabigatran , Atrial Fibrillation , Empagliflozin , Clinical endpoint
891
One Index
 Ettore D Capoluongo 4 docs (2024 - 2024)  
Health Technology Assessment , Leverage (statistics) , Health technology
889
One Index
 Broedl, Uli PhD   0000-0001-9893-7747 138 docs (2002 - 2024)  
Empagliflozin , Type 2 Diabetes , Insulin Therapy , EMPA , Diabetes
874
One Index
 Woerle, Hans-Juergen PhD   0000-0003-2595-1411 181 docs (2000 - 2024)  
Empagliflozin , Linagliptin , Type 2 Diabetes , Insulin Therapy , Diabetes
867
One Index
 Maximilian Von Eynatten PhD 163 docs (2002 - 2024)  
Linagliptin , Type 2 Diabetes , Empagliflozin , Insulin Therapy , Diabetes
842
One Index
 Viollet, Coralie PhD   0000-0002-6182-8165 58 docs (2015 - 2024)  
Genome-wide association study , Lewy body , Genetic association , RNA-Seq , Proteogenomics
834
One Index
 Rehbein, Steffen PhD   0000-0002-8496-8355 159 docs (1993 - 2024)  
Veterinary Parasites , Ostertagia ostertagi , Ostertagia , Mange , Nematodirus
827
One Index
 George, Jyothis PhD   0000-0002-5299-775X 233 docs (1962 - 2024)  
Empagliflozin , EMPA , Type 2 Diabetes , Diabetes , Insulin Therapy
816
One Index
 Koitka‐Weber, Audrey PhD 36 docs (2017 - 2022)  
Empagliflozin , EMPA , Type 2 Diabetes , Albuminuria , Diabetes
814
One Index
 Stefan, Hantel PhD 107 docs (2006 - 2024)  
Empagliflozin , Type 2 Diabetes , EMPA , Dabigatran , Diabetes
813
One Index
 Okafo, George 13 docs (2022 - 2024)  
Genome-wide association study , Genetic association , Concordance , cancer susceptibility , Cancer Risk
813
One Index
 Jung, Marc 13 docs (2022 - 2024)  
Genome-wide association study , Genetic association , Concordance , cancer susceptibility , Cancer Risk
805
One Index
 David Michael Wyatt PhD 296 docs (1963 - 2024)  
Thailand , Hemingway , Content (measure theory) , Burmese , Icon
803
One Index
 Stowasser, Susanne PhD 202 docs (2008 - 2024)  
Nintedanib , Idiopathic Pulmonary Fibrosis , Vital capacity , Clinical endpoint , Interstitial Lung Disease
800
One Index
 Degroote, Matthias PhD   0000-0002-8850-7708 62 docs (2011 - 2024)  
Quantum Simulation , Fault-tolerant Quantum Computation , Quantum Computation , Hamiltonian (control theory) , Adiabatic Quantum Computation
786
One Index
 Mattheus, Michaela PhD   0000-0002-8611-6236 137 docs (2011 - 2024)  
Empagliflozin , EMPA , Type 2 Diabetes , Linagliptin , Insulin Therapy
784
One Index
 Hans Jurgen Woerle PhD 121 docs (2002 - 2019)  
Empagliflozin , Type 2 Diabetes , EMPA , Linagliptin , Insulin Therapy
783
One Index
 Bluhmki, Erich PhD   0000-0002-3846-7226 112 docs (1992 - 2023)  
Stroke (engine) , Infarction Treatment , Meloxicam , Thrombolysis , Empagliflozin
778
One Index
 Pekcec, Anton PhD   0000-0001-9045-4740 69 docs (2006 - 2024)  
P-glycoprotein , Hippocampal Neurogenesis , Epilepsy , Doublecortin , Piriform cortex
772
One Index
 Hengerer, Bastian PhD   0000-0002-7811-9795 151 docs (1988 - 2024)  
Stress , Neurodegeneration , a-Synuclein , Nerve Regeneration , Antidepressant Treatment
764
One Index
 Garidel, Patrick PhD   0000-0001-9512-9533 210 docs (1996 - 2024)  
Protein Aggregation , Isothermal titration calorimetry , Polysorbate , Lipid A , Particle (ecology)
761
One Index
 Quaresma, Manuel PhD   0000-0002-2192-6713 117 docs (2015 - 2023)  
Nintedanib , Idiopathic Pulmonary Fibrosis , Vital capacity , Interstitial Lung Disease , Generalized pustular psoriasis
761
One Index
 Zeller, Cordula PhD   0000-0002-0639-8836 47 docs (2013 - 2023)  
Empagliflozin , Type 2 Diabetes , EMPA , Clinical endpoint , Treatment
755
One Index
 Søren Søgaard Lund PhD 85 docs (2001 - 2024)  
Empagliflozin , Type 2 Diabetes , Diabetes , Insulin Therapy , Insulin Signaling
746
One Index
 Déruaz-Luyet, Anouk PhD   0000-0001-7396-7392 73 docs (2015 - 2024)  
Empagliflozin , Type 2 Diabetes , Patient Complexity , EMPA , Multimorbidity